So... THIS Is Why It Might Be Good Idea -- To Solve The Name Confusion -- Between US, And German "Mercks": Bloomberg Still Getting It Wrong.

Don't misunderstand -- Bloomberg is a great news outlet. It has generally very reliable business and law stories, and pharma- ones. [And it may have left some interns in charge of final edits -- on videos -- on Good Friday afternoon, for all we know.]

But over the at least last 15 years, we've documented at least ten or more news outlets (besides Bloomberg and the WSJ) -- including the EU-based ones -- that have run stories and pictures, and video. . . referring to the "wrong" Merck. . . in the outlet's own story. So too, again -- here on Good Friday just passed.

It is crystal clear they mean Rob's US based firm (with copious references to the PAH biologic approval at FDA this week, no less!) -- but the High-Def video open all weekend. . . is of the German firm's HQ, in the gloaming -- at. . . Darmstadt.

By late on Easter Sunday, the editors had corrected the video -- but this is precisely why either a settlement or litigation must ensue. People may begin buying the German firm, thinking they get the US powerhouse's earnings -- when in fact, the German firm is now a waif, by comparison. Here's the corrected link:

. . .Merck Chair and CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure. Speaking on Bloomberg Television, Davis also comments on Merck's development of an obesity-fighting drug and health-care costs. (Video edited to remove incorrect graphics). . . .

Now you know -- let's be careful out there folks. . . onward, to the Women's LSU v. Iowa rematch, on Monday evening! Grin. . . and a very Happy Easter to the sweet, but rapidly-growing pair, in Music City, this afternoon. . . .

नमस्ते